Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267860 | 0.91 | ADORA2A (0.85) | ADORA2AADORA1 | |
| SCHEMBL3268210 | 0.89 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL5451814 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL5459643 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL5463659 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL5461268 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL5452425 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL3267851 | 0.88 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL3268508 | 0.88 | ADORA2A (0.85) | ADORA2AADORA1 | |
| SCHEMBL5459569 | 0.88 | ADORA2A (0.78) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349857-B1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | ADORA2A 14/4885ADORA1 17/4885 |
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | ADORA2A 96/4885ADORA1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.